INBX
NASDAQInhibrx Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$88.03-1.53 (-1.71%)
01:30 PM07:45 PM
News · 26 weeks28-62%
2025-12-142026-06-07
Mix2290d
- SEC Filings9(41%)
- Other6(27%)
- Insider5(23%)
- Analyst1(5%)
- Earnings1(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Vuori Kristiina Md4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERSEC Form 4 filed by Director Kayyem Jon Faiz4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERSEC Form 4 filed by Director Forsyth Douglas4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERSEC Form 4 filed by Director Manhard Kimberly4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.SCHEDULE 13G/A - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.SCHEDULE 13G/A - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- SECSEC Form 10-Q filed by Inhibrx Biosciences Inc.10-Q - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- PRInhibrx Reports First Quarter 2026 Financial ResultsSAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Recent Corporate Highlights and Upcoming MilestonesINBRX-106In May 2026, we announced updated interim data from our randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizuma
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- PRInhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 MonotherapyInterim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab combination achieved a cORR of 44.0% versus 21.4% with pembrolizumab alone, representing a 22.6% absolute increase in cORR.Superior depth of response: Responding patients in the combination arm demonstrated deeper tumor reductions overall, with the majority achieving target lesion shrinkage exceeding 50%; notably, three patients achieved a complete radiographic response.Up to 15-fold mean increase in systemic T-Cell expansion: Peripheral blood analysis showed robust CD8+ and CD4+ T-cell proliferati
- PRInhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT –SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Monday, May 11, 2026 at 5:30 a.m. Pacific Time to provide interim results from the randomized, first-line Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-li
- INSIDERSEC Form 4 filed by President Matly David4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- SECSEC Form DEFA14A filed by Inhibrx Biosciences Inc.DEFA14A - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- SECSEC Form DEF 14A filed by Inhibrx Biosciences Inc.DEF 14A - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- PRInhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal CancerSAN DIEGO, April 21, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced updated interim data from its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). As of April 10, 2026, the cutoff date, the CRC cohort continued to demonstrate a compelling signal of activity in a heavily pretreated patient population. Of t
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- ANALYSTStifel initiated coverage on Inhibrx Biosciences with a new price targetStifel initiated coverage of Inhibrx Biosciences with a rating of Buy and set a new price target of $150.00
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- SECSEC Form 10-K filed by Inhibrx Biosciences Inc.10-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- PRInhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial ResultsSAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. (the "Acquirer") and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials. Upcoming Milestonesozekibart (INBRX-109)We expect to submit the Biologics License Applicati
- PRInhibrx Announces Participation in Upcoming Scientific ConferenceSAN DIEGO, March 2, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conference: ESMO Sarcoma and Rare Cancers CongressMarch 12th- 14th, 2026; Lugano SwitzerlandTitle: Phase 1 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined With Irinotecan (I) and Temozolomide (T) in Adolescents and Adults With Ewing SarcomaAbstract number: 84
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.SCHEDULE 13G/A - Inhibrx Biosciences, Inc. (0002007919) (Subject)
INBX FAQ
6 questionsWhat does Inhibrx Biosciences Inc. do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein...Where does INBX stock trade?
Inhibrx Biosciences Inc. (INBX) is listed on NASDAQ.What sector and industry is INBX in?
Inhibrx Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about INBX?
Inhibrx Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy on 2026-04-08. Recent price targets range from $4000.00 to $4600.00.What companies are similar to INBX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare INBX side-by-side with any of them on Quantisnow.How can I track INBX on Quantisnow?
Quantisnow aggregates Inhibrx Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INBX to receive live email and push alerts on every new disclosure.